These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11771732)

  • 1. Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2.
    Honda M; Okuda T; Hasegawa T; Kurokawa M; Shiraki K; Matsuo K; Komatsuzaki M; Niimura M
    Antivir Chem Chemother; 2001 Jul; 12(4):233-9. PubMed ID: 11771732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subclinical generation of acyclovir-resistant herpes simplex virus with mutation of homopolymeric guanosine strings during acyclovir therapy.
    Daikoku T; Tannai H; Honda M; Onoe T; Matsuo K; Onoye Y; Nishizawa M; Kawana T; Okuda T; Hasegawa T; Shiraki K
    J Dermatol Sci; 2016 Jun; 82(3):160-5. PubMed ID: 26917345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: models for antiviral evaluations.
    Bernstein DI; Ireland J; Bourne N
    Antiviral Res; 2000 Sep; 47(3):159-69. PubMed ID: 10974368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Isolation of acyclovir-resistant strains of herpes simplex virus from clinical material].
    L'vov ND; Andronova VL; Leont'eva NA; Galegov GA
    Vopr Virusol; 1999; 44(6):247-9. PubMed ID: 10665057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of acyclovir-resistant herpes simplex viruses isolated from the general immunocompetent population and patients with acquired immunodeficiency syndrome.
    Ziyaeyan M; Alborzi A; Japoni A; Kadivar M; Davarpanah MA; Pourabbas B; Abassian A
    Int J Dermatol; 2007 Dec; 46(12):1263-6. PubMed ID: 18173520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical utility of susceptibility testing of herpes simplex virus to acyclovir].
    Otegui M; Rabella N; Labeaga R; Herrero M; Margall N; Muñoz JM; Prats G
    Rev Esp Quimioter; 2001 Dec; 14(4):351-7. PubMed ID: 11856981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient.
    Pardeiro M; Cuenca-Estrella M; Fernández-Clúa MA; Santos-O'Connor F; Tabarés E; Gadea I
    J Med Virol; 2004 May; 73(1):60-4. PubMed ID: 15042649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis.
    Pechère M; Wunderli W; Trellu-Toutous L; Harms M; Saura JH; Krischer J
    Dermatology; 1998; 197(3):278-80. PubMed ID: 9812037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan.
    Hasegawa T; Kawana T; Okuda T; Horii M; Tsukada T; Shiraki K
    J Med Virol; 2001 Jan; 63(1):57-63. PubMed ID: 11130888
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient.
    Chibo D; Mijch A; Doherty R; Birch C
    J Clin Virol; 2002 Aug; 25(2):165-70. PubMed ID: 12367650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent genital herpes simplex virus 2 shedding in immunocompetent women. Effect of acyclovir treatment.
    Wald A; Corey L; Cone R; Hobson A; Davis G; Zeh J
    J Clin Invest; 1997 Mar; 99(5):1092-7. PubMed ID: 9062368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Administration of oral acyclovir suppressive therapy after neonatal herpes simplex virus disease limited to the skin, eyes and mouth: results of a phase I/II trial.
    Kimberlin D; Powell D; Gruber W; Diaz P; Arvin A; Kumar M; Jacobs R; Van Dyke R; Burchett S; Soong SJ; Lakeman A; Whitley R
    Pediatr Infect Dis J; 1996 Mar; 15(3):247-54. PubMed ID: 8852914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics.
    Reyes M; Shaik NS; Graber JM; Nisenbaum R; Wetherall NT; Fukuda K; Reeves WC;
    Arch Intern Med; 2003 Jan; 163(1):76-80. PubMed ID: 12523920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus.
    Shimada Y; Suzuki M; Shirasaki F; Saito E; Sogo K; Hasegawa M; Takehara K; Phromjai J; Chuhjo T; Shiraki K
    J Med Virol; 2007 Nov; 79(11):1731-40. PubMed ID: 17854045
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients.
    Gaudreau A; Hill E; Balfour HH; Erice A; Boivin G
    J Infect Dis; 1998 Aug; 178(2):297-303. PubMed ID: 9697707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid screen test for in vitro susceptibility of clinical herpes simplex virus isolates.
    Safrin S; Elbeik T; Mills J
    J Infect Dis; 1994 Apr; 169(4):879-82. PubMed ID: 8133105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two-day regimen of acyclovir for treatment of recurrent genital herpes simplex virus type 2 infection.
    Wald A; Carrell D; Remington M; Kexel E; Zeh J; Corey L
    Clin Infect Dis; 2002 Apr; 34(7):944-8. PubMed ID: 11880960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of generation and replication of acyclovir-resistant herpes simplex virus by a sensitive virus.
    Okuda T; Kurokawa M; Matsuo K; Honda M; Niimura M; Shiraki K
    J Med Virol; 2004 Jan; 72(1):112-20. PubMed ID: 14635018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of valacyclovir on viral shedding in immunocompetent patients with recurrent herpes simplex virus 2 genital herpes: a US-based randomized, double-blind, placebo-controlled clinical trial.
    Fife KH; Warren TJ; Ferrera RD; Young DG; Justus SE; Heitman CK; Burroughs SM
    Mayo Clin Proc; 2006 Oct; 81(10):1321-7. PubMed ID: 17036557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent antiviral-resistant genital herpes in an immunocompetent patient.
    Kriesel JD; Spruance SL; Prichard M; Parker JN; Kern ER
    J Infect Dis; 2005 Jul; 192(1):156-61. PubMed ID: 15942905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.